Anti-VEGFs improve vision at 2 years in eyes with diabetic macular edema

Three anti-VEGFs with a standardized follow-up and re-treatment regimen improved visual acuity at 2 years in eyes with diabetic macular edema, according to a study.The Diabetic Retinopathy Clinical Research Network Protocol T study compared the effectiveness of Eylea (aflibercept, Regeneron), Avastin (bevacizumab, Genentech) and Lucentis (ranibizumab, Genentech) in the treatment of center-involved DME associated with visual impairment.